Proliferative T-cell responses to poliovirus in various strains of mice have been analyzed by using either killed purified virus or capsid protein VP1 synthetic peptides. Following immunization of mice with inactivated poliovirus type 1 (PV1), a specffic proliferative response of their lymph node CD4+ T cells was obtained after in vitro stimulation with purified virus. In mice immunized with PV1, PV2, or PV3, a strong cross-reactivity of the T-cell responses was observed after in vitro stimulation with heterologous viruses. By using various strategies, a dominant T-cell epitope was identified in the amino acid 103 to 115 region of capsid polypeptide VP1, close by the C3 neutralization epitope. The T-cell response to VP1 amino acids 103 to 115 is H-2 restricted: H-2d mice are responders, whereas H-2k and H-2b mice do not respond to this T-cell epitope. Immunization of BALB/c (H-2d) mice with the uncoupled p86-115 peptide, which represents VP1 amino acids 86 to 115 and contains both the T-cell epitope and the C3 neutralization epitope, induced poliovirus-specific B-and T-cell responses. Moreover, these mice developed poliovirus neutralizing antibodies.
Specific antibodies capable of neutralizing virus infectivity are considered to be the major mechanism of protection against poliovirus infection. Therefore, many studies have been performed to define the antigenic structures involved in poliovirus neutralization and have resulted in the identification of several neutralization epitopes. The protein capsid of poliovirus is composed of 60 copies each of four polypeptides VP1, VP2, VP3, and VP4. Its three-dimensional structure has been solved at a resolution of 0.29 nm (14) . Four major neutralization antigenic sites have been identified on the three major capsid proteins of polioviruses (23, 25) . Site 1 is composed of residues from VP1, whereas the structures of the other antigenic sites appear to be more complex, involving residues from VP1, VP2, and/or VP3 (23, 25) .
A continuous neutralization epitope (C3 epitope) of site 1 of poliovirus type 1 (PV1), recognized by neutralizing monoclonal antibody C3, is expressed on native (D) and heattreated (C) viral particles as well as on isolated capsid polypeptide VP1 (2, 15) . By using various strategies, investigators have localized this epitope within the region of VP1 from amino acids 93 to 104 (29, 30) . According to the three-dimensional structure of the capsid, this region forms an exposed loop (BC loop), located around the fivefold axes of the virion, and is flanked by two P-strands corresponding to VP1 residues 82 to 95 and 105 to 109. Most interestingly, for poliovirus type 2 (PV2), the amino acid sequence of VP1 from residues 93 to 104 is also involved in mouse neurovirulence and is an important determinant of the poliovirus host range (20, 24) . Protein conjugates or peptides containing the region of VP1 from amino acids 93 to 103 have been shown by several groups to induce poliovirus-specific antibodies and a low level of neutralizing antibodies in rabbits (8, 15) or rats (4) . More induce antiviral as well as neutralizing anti-poliovirus antibodies in mice and rabbits (3, 5, 6, 18, 28) .
These studies indicate that neutralization antigenic site 1 of PV1 contains an important B-cell epitope. Moreover, our preliminary results on the immunogenicity of free synthetic peptides containing the amino acid 93 to 103 epitope as well as residues from the flanking p-strands suggest that this region could also contain a dominant T-cell epitope (27a). The T-cell responses to poliovirus antigens have not been studied so far. Therefore, the present study was undertaken to analyze these T-cell responses and has permitted the identification of a dominant T-cell epitope adjacent to neutralization antigenic site 1 of PV1.
MATERIALS AND METHODS
Mice. Female BALB/c (H-2d), BALB.B (H-2b), DBA/2 (H-2d), C57BL/6 (H-2b) and C3H/He (H-2) mice, 6 (Fig. 2) . This poliovirus-specific proliferative response was due to the stimulation of the CD4+ T-cell subset, since the poliovirus-specific proliferation of LN cells from PV1-primed BALB/c mice was totally inhibited by the addition to the culture of anti-CD4+ monoclonal antibodies but was not affected by coculture with anti-CD8+ monoclonal antibodies even at high doses (Fig. 3) .
To examine the serotype specificity of poliovirus-specific T-cell proliferative responses, we immunized BALB/c mice amino-acid region of capsid protein VP1 has been deleted by site-directed mutagenesis of the PV1 cDNA (12) . Two weeks later, we stimulated LN cells of the mice in vitro with various doses of inactivated PV1, PV2, PV3, or vA9. The best proliferative responses of these cultures were obtained with 0.1 ,ug of the various viruses and are shown in Fig. 4 . In all cases, the highest levels of proliferation were obtained in response to the homologous virus, but strong cross-reactiv- Proliferative responses of PV1-primed lymphocytes to synthetic peptides from PV1 neutralization antigenic site 1. Lymphocytes from PV1-primed BALB/c mice were stimulated in vitro with various synthetic peptides representing PV1 neutralization antigenic site 1. Peptides of various length, corresponding to the region of amino acid residues 79 to 116 of VP1, were tested (Fig. 1) . No significant proliferative responses were obtained following stimulation of LN cells with p95-104, p(93-103)3 or p79-103 (Fig. SA) . In contrast, these cells did proliferate when incubated with p93-116 and p86-115, indicating that the VP1 region of amino acids 93 to 115 could contain a T-cell epitope. To localize the T-cell epitope more precisely, we analyzed proliferative responses to a series of peptides corresponding to the region of amino acids 90 to 116 of VP1 (Fig. 5B) . LN cells from PV1-primed mice did not proliferate with p90-101, p95-106, or plO1-111, whereas significant proliferative responses were obtained following stimulation with p103-116 and, to a lesser extent, with p105-116. These observations indicate that the T-cell epitope is located between residues 103 and 116 of VP1. Moreover, LN cells from vA&9-primed BALB/c mice responded as well to p86-115 as did the cells from PV1-primed mice (Fig. 6 ). Since the region from amino acids 94 to 102 has been deleted in vA9, this confirms that the putative T-cell epitope is located between residues 103 and 115 of VP1. Interestingly, LN cells from PV2-primed mice responded well to p86-115 (approximately half the response of the PV1-primed lymphocytes), whereas LN cells from PV3-primed mice responded only weakly. It should be noticed that the VP1 sequences from amino acids 103 to 115 of PV1 and PV2 differ only by one amino acid residue, whereas those of PV1 and PV3 differ by two residues (Fig. 1) .
H-2 restriction of proliferative response to p86-115. Various inbred strains of mice, BALB/c (H-2d), DBA/2 (H-2d), C57BL/6 (H-2b), and C3H/He (H-2k), were immunized in vivo with 1 jig of inactivated PV1, and 2 weeks later their LN cells were stimulated in vitro either with PV1 or with p86-115. Various doses of antigens were used. Figure 7 shows the best proliferative responses obtained in a representative experiment. A proliferative response to PV1 was observed in all strains of mice tested, although the LN-cell response of the C57BL/6 mice was usually weaker than that of the other strains of mice. None of these mice responded to p79-103 or p(93-103)3. C57BL/6 and C3H/He LN cells did not proliferate when incubated with p93-116 or p86-115. In contrast, a proliferative response to these peptides was observed with LN cells from BALB/c and DBA/2 mice primed with PV1. These data could indicate that PV1 contains a T-cell epitope included in VP1 residues 103 to 115 and recognized by H-2d but not by H-2b or H-2k mice. To confirm this result, we repeated the experiment with H-2 congenic strains of mice. LN cells from PV1-primed BALB/c (H-2d), BALB.B (H-2b), or BALB.K (H-2k) mice responded equally well to in vitro stimulation with inactivated PV1 (Fig. 8) . In contrast, only LN cells from BALB/c mice proliferated in response to p86-115. Therefore, p86-115 contains a T-cell determinant recognized in the context of the H-2d haplotype but not in that of the H-2b or H-2k haplotype.
Immunogenicity of peptide p86-115. Since p86-115 contains the C3 epitope (amino acids 93 to 103) as well as a T-cell epitope, we inferred that immunization with this peptide would induce poliovirus-specific B-and T-cell responses. We examined the ability of p86-115 to induce T-cell responses in congenic strains of mice. BALB/c, BALB.B, and BALB.K mice were immunized in vivo with 30 ,g of p86-115, and LN cells were stimulated in vitro either with inactivated PV1 or with p86-115. Control BALB/c mice were immunized either with PV1 or with an unrelated hepatitis B virus pre-S peptide, p120-145 (Fig. 9) . LN significant response to inactivated PV1 could also be demonstrated. As expected from the previous experiment, LN cells from p86-115-primed BALB.B or BALB.K mice responded neither to the peptide nor to PV1. Therefore, in H-2d mice, a poliovirus-specific T-cell response can be induced by immunization with the free p86-115 peptide. To determine whether a poliovirus-specific B-cell response could be induced with the same peptide, we examined the ability of p86-115 to induce a poliovirus-specific antibody response in BALB/c (responder) or C3H/He (nonresponder) mice. In BALB/c mice only one injection of the peptide was sufficient to induce high antibody titers against either the C3 epitope or the p86-115 peptide (Table 1) . Moreover, after two injections, the serum of these mice did recognize the infectious (anti-D) or heat-treated (anti-C) virions. Four of five mice also developed poliovirus neutralizing antibodies. In contrast, even after two injections of peptides, serum from immunized C3H/He mice recognized neither the peptides nor the virus.
DISCUSSION
The present study demonstrates that immunization with inactivated, purified poliovirus induces a specific CD4' T-cell response. Moreover, the use of various strategies permitted the identification of a dominant T-cell epitope in the amino acid 103 to 115 region of capsid polypeptide VP1.
A high degree of cross-reactivity of T-cell proliferative responses to poliovirus was observed for PV1, PV2, and PV3 serotypes, the strongest cross-reactivity occurring be- tween PV1 and PV2. The VP1 regions of PV1 and PV2 between amino acids 103 and 115 differ only by one amino acid residue, and priming by PV2 induced a strong T-cell response against a synthetic peptide containing the VP1 103 to 115 region of PV1. The identification of a common T-cell site on these two poliovirus serotypes could therefore explain this strong T-cell cross-reactivity. In contrast, a twoamino-acid difference exists between PV1 and PV3 in this region, and PV3-primed T cells responded only weakly to the PV1 p86-115 peptide. However, these cells proliferated in response to purified PV1 and PV2. These data indicate that at least a second dominant T-cell site, which could be common to all three serotypes, must exist on VP1, VP2, VP3, or VP4. Evidence for a cross-reacting T-cell epitope common to several enteroviruses was recently reported (1) . Such a putative T-cell epitope(s) could be identified by comparing the sequences of the four capsid polypeptides of the three polioviruses and of other enteroviruses. These results could be important for designing a synthetic vaccine of broad specificity.
This study demonstrates that neutralization antigenic site 1 of PV1 contains both B and T-helper (Th) epitopes. Such short peptides containing B and T epitopes have been described for other viruses such as hepatitis B virus (22) and foot-and-mouth disease virus (10, 11 a major role in the immunogenicity of the C3 epitope. Therefore, it could be suggested that to confer optimal immunogenicity to the epitopes grafted in antigenic site 1, the chimeras have to be built without deleting the amino acid region (amino acids 103 to 115) containing the C3 Th site. Immunization with the uncoupled p86-115 peptide induced poliovirus-specific B-and T-cell responses in the responder strain of mice (H-2d) but not in nonresponder strains such as H-2k. Moreover, 80o of the H-2d mice immunized with this peptide developed poliovirus-specific neutralizing antibodies. This clearly demonstrates that the T-cell epitope at amino acids 103 to 115 is a T-helper site and that the induction of an antibody response against the C3 epitope by the free p86-115 peptide requires the responsiveness of T cells to the peptide. High neutralizing-antibody titers were also obtained in rabbits immunized with free peptides representing VP1 amino acids 82 to 116 or 93 to 115 (27a). The C3 Th site could therefore also function as a T-helper epitope in rabbits. It has been previously demonstrated that synthetic vaccines could be constructed by appropriate selection and organization of B-and T-cell determinants (13, 19, 21, 26) . The present study demonstrates the feasibility of such an approach for poliovirus. Moreover, it is also possible that a vaccine protecting against the three poliovirus serotypes could be designed by the selection of appropriate B-and T-cell cross-reactive or common epitopes.
